Remove Laboratories Remove Protein Expression Remove Protein Production Remove Virus
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

The luncheon presentation will be done by James Keck, PhD, President’s Innovation Fellow and Senior Director, Innovation and Product Development, Product Development, The Jackson Laboratory. CCO & Co-Founder, ATUM, on: “Using machine learning to predict protein expression”. Claes Gustafsson, Ph.D,

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The luncheon presentation will be given by Hans Gerstmans, Postdoctoral Researcher, Laboratory for Biomolecular Discovery & Engineering, KU Leuven, VIB, alongside Wai Long Tam, Head of Technology Watch at VIB, Technology Watch, VIB. The session ends with two presentations and two luncheon presentations.

article thumbnail

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.